Market Overview

UPDATE: Piper Jaffray Raises PT to $21 on Globus Medical

Globus Medical Analyst Roundup Following Preliminary Q4 Results
UPDATE: Oppenheimer Raises PT On Globus Medical On Pre-Announced 4Q14 Revenue

Piper Jaffray reiterated its Overweight rating on Globus Medical (NYSE: GMED) and raised its price target from $18 to $21.

Piper Jaffray noted, "FDA clearance of Globus's cervical total disc replacement system, Secure-C, will be an important catalyst for growth for the company heading into 2013. Management had set 2H12 as the targeted timeframe for approval, so on the one hand approval might be viewed as in line with expectations. … The disc opens up around $200-300 mil of additional market opportunity by our estimate, and should help drive traction for the company with new surgeons. We reiterate our Overweight rating on GMED, upping our target from $18 to $21, and remain buyers of the stock at current levels."

Globus Medical closed at $18.03 on Friday.

Latest Ratings for GMED

Jul 2015Leerink SwannMaintainsOutperform
Apr 2015Wells FargoInitiates Coverage onOutperform
Feb 2015Leerink SwannMaintainsOutperform

View More Analyst Ratings for GMED
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Price Target Intraday Update Analyst Ratings


Related Articles (GMED)

View Comments and Join the Discussion!

Get Benzinga's Newsletters